Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2005 1
2006 2
2007 5
2010 1
2011 2
2012 1
2013 2
2014 1
2015 1
2016 1
2017 2
2018 4
2019 2
2020 5
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Results by year
Filters applied: . Clear all
Page 1
Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure.
Tojima H, Kakizaki S, Takakusagi S, Hoshino T, Naganuma A, Nagashima T, Namikawa M, Ueno T, Shimada Y, Hatanaka T, Takizawa D, Arai H, Sato K, Takagi H, Uraoka T. Tojima H, et al. Among authors: arai h. Hepatol Res. 2020 Mar;50(3):303-312. doi: 10.1111/hepr.13462. Epub 2019 Dec 19. Hepatol Res. 2020. PMID: 31750974
Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment.
Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Ueno T, Tojima H, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Hatanaka T, et al. Among authors: arai h. Cancers (Basel). 2020 Oct 10;12(10):2906. doi: 10.3390/cancers12102906. Cancers (Basel). 2020. PMID: 33050527 Free PMC article.
Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study.
Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Tojima H, Shimada Y, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Hatanaka T, et al. Among authors: arai h. Hepatol Res. 2020 Mar;50(3):382-395. doi: 10.1111/hepr.13460. Epub 2019 Dec 10. Hepatol Res. 2020. PMID: 31760660
A Rare Cause of Esophageal Varices.
Suga T, Arai H, Takayama H. Suga T, et al. Among authors: arai h. Gastroenterology. 2016 Jun;150(7):1533-1534. doi: 10.1053/j.gastro.2016.02.021. Epub 2016 Apr 30. Gastroenterology. 2016. PMID: 27140485 No abstract available.
The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
Hatanaka T, Naganuma A, Shibasaki M, Kohga T, Arai Y, Nagashima T, Ueno T, Namikawa M, Saito S, Hoshino T, Takizawa D, Arai H, Makita F, Kakizaki S, Harimoto N, Shirabe K, Uraoka T. Hatanaka T, et al. Among authors: arai h. Oncology. 2021;99(4):203-214. doi: 10.1159/000511734. Epub 2020 Dec 4. Oncology. 2021. PMID: 33279908
Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection.
Takaoka Y, Miura K, Morimoto N, Ikegami T, Kakizaki S, Sato K, Ueno T, Naganuma A, Kosone T, Arai H, Hatanaka T, Tahara T, Tano S, Ohtake T, Murohisa T, Namikawa M, Asano T, Kamoshida T, Horiuchi K, Nihei T, Soeda A, Kurata H, Fujieda T, Ohtake T, Fukaya Y, Iijima M, Watanabe S, Isoda N, Yamamoto H; Liver Investigators in the Northern Kanto Study (LINKS) group. Takaoka Y, et al. Among authors: arai h. Hepatol Res. 2021 Jan;51(1):51-61. doi: 10.1111/hepr.13576. Epub 2020 Oct 20. Hepatol Res. 2021. PMID: 33021009
Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin.
Sato K, Naganuma A, Nagashima T, Hoshino T, Uehara D, Arai Y, Horiuchi K, Yuasa K, Takayama H, Arai H, Hatanaka T, Ohyama T, Tahara H, Sohara N, Kobayashi T, Horiguchi N, Yamazaki Y, Kakizaki S, Kusano M, Yamada M, Murase T, Nakamura T. Sato K, et al. Among authors: arai h. Hepatol Res. 2018 Feb;48(3):E347-E353. doi: 10.1111/hepr.12971. Epub 2017 Sep 25. Hepatol Res. 2018. PMID: 28834004
33 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page